Project Grant R24AI191868
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$722K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
The University of California, Los Angeles (UCLA) was awarded a $415,876 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) by the National Institutes of Health Office of the Director, with a performance period from August 1, 2024 to July 31, 2026. The purpose of this grant is to optimize and utilize a novel five-dimensional (5D) magnetic resonance spectroscopic imaging (MRSI) technique called "ROSE-JRESI" and three-dimensional myelin water imaging (MWI) to study...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,576,238 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Miami. The grant will fund a project titled "Leveraging a Strategic Alliance of Community-Based Implementers and Researchers to Characterize, Protocolize, and Scale Up Local Implementation Strategies for Ending the HIV Epidemic Among Latino MSM." The project aims to characterize, assess, and...
This Project Grant award of $1,246,486 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the "ACCELERATING PUBLIC HEALTH IMPACT THROUGH THE UNIVERSITY OF WASHINGTON/NASTAD RESEARCH ALLIANCE IN IMPLEMENTATION SCIENCE TO END HIV (RAISE) REGIONAL CONSULTATIVE HUB" to enhance the impact of the Ending the HIV Epidemic (EHE) initiative. The key products and services to be delivered under this award include:...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,155,836 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Miami. The funding will support a 5-year, randomized hybrid implementation/effectiveness trial titled "TEST-TO-PREP: A Randomized Hybrid Implementation/Efficacy Trial of a Social Network Strategy to Increase Equitable Reach of HIV Testing and PrEP Information." The study aims to evaluate the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $820,845 to New York University School of Medicine to conduct research aimed at improving HIV outcomes across diverse settings and subgroups in the U.S. HIV epidemic. The research will use mathematical modeling to simulate alternative ways to distribute resources across interventions, settings, and target...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of California, Davis. The grant, titled "OPTIMAL T-CELL SUPPORT FOR HIV NEUTRALIZING ANTIBODY INDUCTION TO FUSION PEPTIDE-INCLUSIVE REGIMENS (OPTI-FLIP)", will fund the development of an HIV vaccine regimen that elicits cooperative interactions between fusion peptide-directed...
This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
This Project Grant award of $343,744 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a comprehensive strategy for an Investigational New Drug (IND) submission and clinical development of a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy to functionally cure HIV infection. The key products and services to be delivered include: 1) Formulating a strategic plan...
This Project Grant award of $856,202 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), which oversees the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award will fund a 5-year study led by researchers at the University of California, San Francisco (UCSF) to investigate the role of IL-10 and IFN signaling in controlling the HIV reservoir and achieving functional HIV cure. The project aims to determine if enhancing IL-10 and...